We are thrilled to share the positive results from Phase 1 of our MAINTAIN trial!

Our lead candidate, EXL01, has successfully demonstrated excellent safety and tolerability in patients with Crohn’s disease over a six-month period.

We successfully met the primary endpoint defined for Part A of our Phase 1 study. After careful consideration, we concluded the study at this stage, reflecting recruitment challenges in the IBD field. Undeterred, we remain committed to advancing innovation.

Next, we’re excited to move forward with MAINTAIN-POP, a Phase 2 trial in postoperative Crohn’s disease, starting in Q1 2025, to further explore EXL01's potential in IBD.

At Exeliom, we are committed to advancing our pipeline and improving outcomes for patients. We’ll be sharing updates on the progress of this trial in early 2025.

Stay tuned for more updates!